4.7 Review

Nanomedicine-based immunotherapy for central nervous system disorders

期刊

ACTA PHARMACOLOGICA SINICA
卷 41, 期 7, 页码 936-953

出版社

NATURE PUBL GROUP
DOI: 10.1038/s41401-020-0429-z

关键词

central nervous system disorders; blood-brain barrier; nanomedicine; immunotherapy

资金

  1. National Natural Science Foundation of China [31600809, 31800841, U1604177, U1804139]
  2. National Key Technologies R&D Program of China [2018YFA0209800]
  3. Australian Endeavour Fellowship [69172018]
  4. Mason Foundation National Medical Program [MAS2017F034]
  5. National Health and Medical Research Council (NHMRC) [GNT1166024]
  6. Dementia Fellowship [GNT1111611]

向作者/读者索取更多资源

Central nervous system (CNS) disorders represent a broad spectrum of brain ailments with short- and long-term disabilities, and nanomedicine-based approaches provide a new therapeutic approach to treating CNS disorders. A variety of potential drugs have been discovered to treat several neuronal disorders; however, their therapeutic success can be limited by the presence of the blood-brain barrier (BBB). Furthermore, unique immune functions within the CNS provide novel target mechanisms for the amelioration of CNS diseases. Recently, various therapeutic approaches have been applied to fight brain-related disorders, with moderate outcomes. Among the various therapeutic strategies, nanomedicine-based immunotherapeutic systems represent a new era that can deliver useful cargo with promising pharmacokinetics. These approaches exploit the molecular and cellular targeting of CNS disorders for enhanced safety, efficacy, and specificity. In this review, we focus on the efficacy of nanomedicines that utilize immunotherapy to combat CNS disorders. Furthermore, we detailed summarize nanomedicine-based pathways for CNS ailments that aim to deliver drugs across the BBB by mimicking innate immune actions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据